rAvPAL-PEG
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria
Trial Timeline
Mar 1, 2011 → Apr 1, 2015
NCT ID
NCT01212744About rAvPAL-PEG
rAvPAL-PEG is a phase 2 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT01212744. Target conditions include Phenylketonuria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01212744 | Phase 2 | Completed |
| NCT00924703 | Phase 2 | Completed |
| NCT00634660 | Phase 1 | Completed |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |